Regeneron Pharmaceuticals SVP Neil Stahl Sells 11,646 Shares (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN) SVP Neil Stahl sold 11,646 shares of Regeneron Pharmaceuticals stock on the open market in a transaction dated Monday, August 11th. The stock was sold at an average price of $339.96, for a total value of $3,959,174.16. Following the transaction, the senior vice president now directly owns 13,527 shares in the company, valued at approximately $4,598,639. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.14% during mid-day trading on Monday, hitting $338.81. 508,355 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 1-year low of $227.64 and a 1-year high of $352.49. The stock has a 50-day moving average of $307. and a 200-day moving average of $306.5. The company has a market cap of $34.013 billion and a P/E ratio of 96.28.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the prior year, the company posted $1.73 earnings per share. The company’s quarterly revenue was up 45.4% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $10.08 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Regeneron Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $345.94.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.